Advertisement

Journal of Biomedical Science

, Volume 10, Issue 1, pp 120–135 | Cite as

Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: Tetramer assay and therapeutic implications

  • Sun-Lung Tsai
  • I-Shyan Sheen
  • Rong-Nan Chien
  • Chia-Min Chu
  • Hsiu-Chu Huang
  • Yen-Ling Chuang
  • Tzong-Hsien Lee
  • Shuen-Kuei Liao
  • Chen-Lung Lin
  • George C. Kuo
  • Yun-Fan Liaw
Original Paper

Abstract

Both chronic hepatitis B and C virus (HBV and HCV) infections respond ineffectively to current antiviral therapies. Recent studies have suggested that treatment outcomes may depend on the development of type 1 T helper (Th1) and Th2 cell responses. Specifically, activation of Th1 immunity may play a major role in successfully treating hepatitis B and C. This model was revisited herein by evaluating immune responses in 36 HBV and 40 HCV patients with or without treatment, in an attempt to find a common immune mechanism for successful treatment. The immune responses in all examined cases were studied by peripheral blood mononuclear cell (PBMC) proliferation and cytokine responses to viral antigens, cytotoxic T lymphocyte (CTL) responses, enzyme-linked immunospot (ELISPOT) assay, and tetramer staining of virus-specific CD8+ T cells. The overall results revealed that all responders among both HBV- and HCV-infected cases displayed significantly higher PBMC proliferation to viral antigens with a predominant Th1 cytokine profile. Furthermore, the Th1-dominant responses were associated with significant enhancement of CTL activities and were correlated with ELISPOT data, while non-responders responded more weakly. During therapy, the numbers of tetramer-staining, virus-specific CD8+ T cells showed greater increases in responders than in non-responders (p=0.001). The frequencies determined by the tetramer assay were approximately 200-fold higher than data estimated by limiting-dilution analysis. In conclusion, activation of Th1 immunity accompanied by enhancement of CTL activity during therapy is a common immune mechanism for successfully treating hepatitis B and C, and therefore may have important therapeutic implications.

Key Words

Antiviral therapy Hepatitis B virus Hepatitis C virus ELISPOT assay Tetramer assay Limiting dilution analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Altman JD, Moss PAH, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94–96;1996.Google Scholar
  2. 2.
    Battegay M, Fikes J, Di Bisceglie AM, Wentworth PA, Sette A, Celis E, Ching WM, Grakoui A, Rice CM, Kurokohchi Kl. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 69:2462–2470;1995.Google Scholar
  3. 3.
    Bertoletti A, Maini MK. Protection or damage: a dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 12:403–408;2000.Google Scholar
  4. 4.
    Bertoni R, Sidney J, Fowler P, Chesnut RW, Chisari FV, Sette A. Human histocompatibility leucocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte respondes in patients with acute hepatitis. J Clin Invest 100:503–513;1997.Google Scholar
  5. 5.
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975;1998.Google Scholar
  6. 6.
    Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 33:963–971;2001.Google Scholar
  7. 7.
    Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot syudy of combinantion therapy with ribavirin plus interferon-alpha for interferon-alpha-resistant chronic hepatitis C. Gastroenterology 107:812–817;1994.Google Scholar
  8. 8.
    Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alpha. Hepatology 24:6–9;1996.Google Scholar
  9. 9.
    Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B, Fowler P, Houghton M, Chisari FV. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 95:521–530;1995.Google Scholar
  10. 10.
    Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100:2376–238;1997.Google Scholar
  11. 11.
    Chen PJ, Lin MH, Tai KF, Liu PC, Lin CJ, Chen DS. The Taiwanese hepatitis C virus genome: sequence determination and mapping the 5′ termini of viral genomic and antigenomic RNA. Virology 188:102–113;1992.Google Scholar
  12. 12.
    Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin α1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 27:1383–1387;1998.Google Scholar
  13. 13.
    Chisari FV. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 156:1118–1132;2000.Google Scholar
  14. 14.
    Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29–60;1995.Google Scholar
  15. 15.
    Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186:1623–1631;1997.Google Scholar
  16. 16.
    Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM. Analysis of a successful immune response against hepatitis C virus. Immunity 10:439–449;1999.Google Scholar
  17. 17.
    Cramp ME, Carucci P, Rossol S, Chokshi S, Maertens G, Williams R, Naoumov NV. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 44:424–429;1999.Google Scholar
  18. 18.
    Desmyter J, Ray MB, De Groot J, Bradburne AF, Desmet VJ, Edy VG, Billiau A, De Somer P. Administration of human fibroblast interferon in chronic hepatitis B infection. Lancet ii:645–647;1976.Google Scholar
  19. 19.
    Doherty PC, Belz GT, Flynn KJ. The continuing revolution in virus-specific CD8+ T cell-mediated immunity. Immunologist 6:173–177;1998.Google Scholar
  20. 20.
    Franco A, Guidotti LG, Hobbs MV, Pasquetto V, Chisari FV. Pathogenetic effect function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 159:2001–2008;1997.Google Scholar
  21. 21.
    Geissler M, Tokushige K, Chante CC, Zurawski VR, Wands JR. Cellular and humoral immune response to hepatitis B virus structural proteins in mice after DNA-based immunization. Gastroenterology 112:1307–1320;1997.Google Scholar
  22. 22.
    Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio T, Pape GR. Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 117:933–941;1999.Google Scholar
  23. 23.
    Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS, Merigan TC. Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 295:517–522;1976.Google Scholar
  24. 24.
    Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, Chisari FV. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 91:3764–3768;1994.Google Scholar
  25. 25.
    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25–36;1996.Google Scholar
  26. 26.
    Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825–829;1999.Google Scholar
  27. 27.
    He XS, Rehermann B, López-Labrador FX, Boisvert J, Cheung R, Humm J, Wedemeyer H, Berenguer M, Wright TL, Davis MM, Greenberg HB. Quantitative analysis of hepatitis C virus-specific CD8+ T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 96:5692–5697;1999.Google Scholar
  28. 28.
    Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 336:347–356;1997.Google Scholar
  29. 29.
    Huang YH, Wu JC, Tao MH, Syu WJ, Hsu SC, Chi WK, Chang FY, Lee SD. DNA-based immunization produces Th1 immune responses to hepatitis delta virus in a mouse model. Hepatology 32:104–110;2000.Google Scholar
  30. 30.
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345:1452–1457;2001.Google Scholar
  31. 31.
    Kamal SM, Rasenack JW, Bianchi L, Tawil AA, Khalifa KES, Peter T, Mansour H, Ezzat W, Koziel M. Acute hepatitis C without and with Schistosomiasis: correlation with hepatitis C-specific CD4+ T-cell and cytokine response. Gastroenterology 121:646–656;2001.Google Scholar
  32. 32.
    Koshy R, Inchauspé G. Evaluation of hepatitis C virus protein epitopes for vaccine development. Trends Biotech 14:364–369;1996.Google Scholar
  33. 33.
    Koziel MJ, Liang TJ. DNA vaccines and viral hepatitis: are we going around in circles? Gastroenterology 112:1410–1414;1997.Google Scholar
  34. 34.
    Koziel MJ. Cytokines in viral hepatitis. Semin Liver Dis 19:157–169;1999.Google Scholar
  35. 35.
    Lagging LM, Meyer K, Hoft D, Houghton M, Belshe RB, Ray R. Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 69:5859–5863;1995.Google Scholar
  36. 36.
    Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 111:1307–1312;1996.Google Scholar
  37. 37.
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 345:41–52;2001.Google Scholar
  38. 38.
    Lee TH, Chuang YL, Tsai SL, Liaw YF. Effects of lamivudine on the hepatitis B virus specific CD8+ cytotoxic T lymphocyte response via peptide-MHC tetrameric complexes assay. Lett Pept Sci 8:179–185;2002.Google Scholar
  39. 39.
    Lee WM. Hepatitis B virus infection. N Engl J Med 337:1733–1745;1997.Google Scholar
  40. 40.
    Liaw YF, Tsai SL. Pathogenesis and clinical significance of spontaneous exacerbations and remissions in chronic hepatitis B virus infection. Vir Hep Rev 3:143–154;1997.Google Scholar
  41. 41.
    Liaw YF, Leung NWY, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172–180;2000.Google Scholar
  42. 42.
    Liaw YF, Tsai SL, Chien RN, Yeh CT, Chu CM. Prednisolone primining enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 32:604–609;2000.Google Scholar
  43. 43.
    Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 29:971–975;1999.Google Scholar
  44. 44.
    Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K, Guidotti LG, Chisari FV, Fikes J, Chesnut RW, Sette A. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 162:2088–2095;1999.Google Scholar
  45. 45.
    Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 — Summary of a workshop. Gastroenterology 120:1828–1853;2001.Google Scholar
  46. 46.
    Maini MK, Casorti G, Dellabona P, Wack A, Beverley PCL. T-cell clonality in immune responses. Immunol Today 20:262–266;1999.Google Scholar
  47. 47.
    Maini MK, Boni C, Ogg GS, King AS, Reignat S, Lee CY, Larrubia JR, Webster GJ, McMichael AJ, Ferrari C, Williams R, Vergani D, Bertoletti A. Direct ex vivo analysis of hepatitis B virus-specific CD8(+)T cells associated with the control of infection. Gastroenterology 117:1386–1396;1999.Google Scholar
  48. 48.
    Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Nauomov NV, Ferrari C, Bertoletti A. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269–1280;2000.Google Scholar
  49. 49.
    Major ME, Vitvitski L, Mink MA, Schleef M, Whalen RG, Trepo C, Inchauspe G. DNA-bases immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol 69:5798–5805;1995.Google Scholar
  50. 50.
    Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel M-L. DNA-mediated immunization in a transgenic mouse model of the hepatitits B surface antigen chronic carrier state. Proc Natl Acad Sci USA 93:12496–12501;1996.Google Scholar
  51. 51.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485–1492;1998.Google Scholar
  52. 52.
    Michel M, Davis HL, Schleef M, Mancini M, Tiollais P, Whalen R. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci USA 92:5307–5011;1995.Google Scholar
  53. 53.
    Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17:138–146;1996.Google Scholar
  54. 54.
    Naoumov NV. Hepatitis C virus-specific CD4+ T cells: do they help or damage? Gastroenterology 117:1012–1014;1999.Google Scholar
  55. 55.
    Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl 2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 160:3487–3493;1998.Google Scholar
  56. 56.
    Penna A, Del Prete G, Cavalli A, Bertoletti A, D'Elios MM, Sorrentino R, D'Amato M, Boni C, Pilli M, Fiaccadori F, Ferrari C. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 25:1022–1027;1997.Google Scholar
  57. 57.
    Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009–1022;2001.Google Scholar
  58. 58.
    Purcell RH. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci USA 91:2401–2406;1994.Google Scholar
  59. 59.
    Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047–1058;1995.Google Scholar
  60. 60.
    Rehermann B, Chang KM, McHutchison J, Kokka R, Houghton M, Rice CM, Chisari FV. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 70:7092–7102;1996.Google Scholar
  61. 61.
    Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 98:1432–1440;1996.Google Scholar
  62. 62.
    Rehermann B. Interaction between the hepatitis C virus and the immune system. Sem Liver Dis 20:127–141;2000.Google Scholar
  63. 63.
    Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, Barkin J, Corless CL, Bouwer HGA. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 117:926–932;1999.Google Scholar
  64. 64.
    Saito T, Sherman GJ, Kurokohchi K, Guo Z-P, Donets M, Yu MYW, Berzofsky JA, Akatsuka T, Feinstone SM. Plasmid DNA-based immunization for hepatitis C virus structural proteins: immuned responses in mice. Gastroenterology 112:1321–1330;1997.Google Scholar
  65. 65.
    Sarobe P, Pendleton CD, Akatsuka T, Lau D, Engelhard VH, Feinstone SM, Berzofsky JA. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding position. J Clin Invest 102:1239–1248;1998.Google Scholar
  66. 66.
    Schirmbec R, Böhm W, Ando K, Chisari FV, Reimann J. Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol 69:5929–5934;1995.Google Scholar
  67. 67.
    Sheen IS, Liaw YF, Lin DY, Chu CM. Acute exacerbations in chronic hepatitis C: a clinicopathological and prognostic study. J Hepatol 24:525–531;1996.Google Scholar
  68. 68.
    Sherman KE, Sjogren M, Creager RL, Damiano MA, Freeman S, Lewey S, Davis D, Root S, Weber FL, Ishak KG. Combination therapy with thymosin α1 and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27:1128–1135;1998.Google Scholar
  69. 69.
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803–806;2000.Google Scholar
  70. 70.
    Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 30:376–382;1999.Google Scholar
  71. 71.
    Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 194:1395–1406;2001.Google Scholar
  72. 72.
    Tokushige K, Wakita T, Pachuk C, Moradpour D, Weiner DB, Zurawski V, Zurawski JRVR, Wands J. Expression and immune response to hepatitis C virus core DNA-bases vaccine constructs. Hepatology 24:14–20;1996.Google Scholar
  73. 73.
    Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 89:87–96;1992.Google Scholar
  74. 74.
    Tsai SL, Chen MH, Yeh CT, Chu CM, Lin AN, Chiou FH, Chang TH, Liaw YF. Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes. J Clin Invest 97:577–584;1996.Google Scholar
  75. 75.
    Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25:449–458;1997.Google Scholar
  76. 76.
    Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, Huang JH, Kuo GC, Liaw YF. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115:954–966;1998.Google Scholar
  77. 77.
    Von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med 343:1021–1034;2000.Google Scholar
  78. 78.
    Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol 150:3438–4345;1993.Google Scholar
  79. 79.
    Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U. CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 159:1012–1018;1997.Google Scholar

Copyright information

© National Science Council 2003

Authors and Affiliations

  • Sun-Lung Tsai
    • 1
  • I-Shyan Sheen
    • 2
  • Rong-Nan Chien
    • 2
  • Chia-Min Chu
    • 2
  • Hsiu-Chu Huang
    • 2
  • Yen-Ling Chuang
    • 2
  • Tzong-Hsien Lee
    • 2
  • Shuen-Kuei Liao
    • 3
  • Chen-Lung Lin
    • 4
  • George C. Kuo
    • 5
  • Yun-Fan Liaw
    • 2
  1. 1.Department of Medical ResearchChi-Mei Medical Center, TainanYung-Kang City, Tainan HsienTaiwan
  2. 2.Liver Research UnitChang Gung Memorial HospitalTaiwan
  3. 3.Graduate Institute of Clinical MedicineChang Gung University College of MedicineTaipeiTaiwan
  4. 4.Department of SurgeryHong Kong University Medical Center, Queen Mary HospitalHong KongTaiwan
  5. 5.Chiron CorporationEmeryvilleUSA

Personalised recommendations